These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. [Cardiovascular effects of GLP-1 receptor agonist treatment: focus on liraglutide]. Haluzík M; Trachta P; Mráz M Vnitr Lek; 2015; 61(7-8):635-40. PubMed ID: 26375689 [TBL] [Abstract][Full Text] [Related]
11. GLP-1 agonism stimulates brown adipose tissue thermogenesis and browning through hypothalamic AMPK. Beiroa D; Imbernon M; Gallego R; Senra A; Herranz D; Villarroya F; Serrano M; Fernø J; Salvador J; Escalada J; Dieguez C; Lopez M; Frühbeck G; Nogueiras R Diabetes; 2014 Oct; 63(10):3346-58. PubMed ID: 24917578 [TBL] [Abstract][Full Text] [Related]
12. Effects of glucagon-like peptide-1 and long-acting analogues on cardiovascular and metabolic function. Saraceni C; Broderick TL Drugs R D; 2007; 8(3):145-53. PubMed ID: 17472410 [TBL] [Abstract][Full Text] [Related]
13. Glucagon-like peptide-1 (GLP-1) receptor agonism or DPP-4 inhibition does not accelerate neoplasia in carcinogen treated mice. Kissow H; Hartmann B; Holst JJ; Viby NE; Hansen LS; Rosenkilde MM; Hare KJ; Poulsen SS Regul Pept; 2012 Nov; 179(1-3):91-100. PubMed ID: 22989472 [TBL] [Abstract][Full Text] [Related]
14. The extra-pancreatic effects of GLP-1 receptor agonists: a focus on the cardiovascular, gastrointestinal and central nervous systems. Seufert J; Gallwitz B Diabetes Obes Metab; 2014 Aug; 16(8):673-88. PubMed ID: 24373150 [TBL] [Abstract][Full Text] [Related]
16. Glucagon-like peptide (GLP)-1(9-36)amide-mediated cytoprotection is blocked by exendin(9-39) yet does not require the known GLP-1 receptor. Ban K; Kim KH; Cho CK; Sauvé M; Diamandis EP; Backx PH; Drucker DJ; Husain M Endocrinology; 2010 Apr; 151(4):1520-31. PubMed ID: 20172966 [TBL] [Abstract][Full Text] [Related]
17. [The value of incretin based therapies]. Gallwitz B Dtsch Med Wochenschr; 2009 May; 134(20):1062-6. PubMed ID: 19421931 [No Abstract] [Full Text] [Related]
18. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Drucker DJ; Nauck MA Lancet; 2006 Nov; 368(9548):1696-705. PubMed ID: 17098089 [TBL] [Abstract][Full Text] [Related]
19. Short-term effects of glucagon-like peptide 1 (GLP-1) receptor agonists on fat distribution in patients with type 2 diabetes mellitus: an ultrasonography study. Morano S; Romagnoli E; Filardi T; Nieddu L; Mandosi E; Fallarino M; Turinese I; Dagostino MP; Lenzi A; Carnevale V Acta Diabetol; 2015 Aug; 52(4):727-32. PubMed ID: 25577244 [TBL] [Abstract][Full Text] [Related]
20. GLP-1 receptor agonist effects on normal and neoplastic pancreata. Goggins M Diabetes; 2012 May; 61(5):989-90. PubMed ID: 22517654 [No Abstract] [Full Text] [Related] [Next] [New Search]